Editas Medicine (EDIT) Operating Margin (2015 - 2025)
Editas Medicine (EDIT) reported Operating Margin of 325.44% for Q3 2025, up 10732374.0% year-over-year from N/an in Q3 2024, and up 77.41% on a QoQ basis from 1440.58% in Q2 2025.
Editas Medicine (EDIT) has 11 years of Operating Margin data on file, last reported at 325.44% in Q3 2025.
- Quarterly Operating Margin rose 10732374.0% year-over-year to 325.44% in Q3 2025, while the trailing twelve-month figure through Sep 2025 was 428.71% (down 5868.0% YoY) and the FY2024 annual result came in at 777.22%, down 56067.0% from the prior year.
- Operating Margin advanced to 325.44% in Q3 2025 per EDIT's latest filing, from 1440.58% in the prior quarter.
- Across five years, Operating Margin topped out at 39.9% in Q4 2023 and bottomed at 136952.38% in Q3 2022.
- The 5-year median for Operating Margin is 940.09% (2023), against an average of 15270.04%.
- The widest annual swing landed in 2022, when Operating Margin plunged 13631896 bps; it then soared 13601229 bps in 2023.
- Tracing EDIT's Operating Margin over 5 years: stood at 333.71% in 2021, then slumped by 191 bps to 970.72% in 2022, then soared by 96 bps to 39.9% in 2023, then tumbled by 282 bps to 152.24% in 2024, then slumped by 114 bps to 325.44% in 2025.
- Per Business Quant, the three latest EDIT Operating Margin figures stand at 325.44% (Q3 2025), 1440.58% (Q2 2025), and 1635.1% (Q1 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 17.83% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 23.02% |
| 10 | Editas Medicine | 338.62 Mn | 338.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -325.44% |
| Jun 30, 2025 | -1,440.58% |
| Mar 31, 2025 | -1,635.10% |
| Dec 31, 2024 | -152.24% |
| Sep 30, 2024 | -107,649.18% |
| Jun 30, 2024 | -14,016.18% |
| Mar 31, 2024 | -5,902.29% |
| Dec 31, 2023 | -39.90% |
| Sep 30, 2023 | -940.09% |
| Jun 30, 2023 | -1,527.33% |
| Mar 31, 2023 | -517.32% |
| Dec 31, 2022 | -970.72% |
| Sep 30, 2022 | -136,952.38% |
| Jun 30, 2022 | -852.47% |
| Mar 31, 2022 | -749.52% |
| Dec 31, 2021 | -333.71% |
| Sep 30, 2021 | -633.42% |
| Jun 30, 2021 | -14,617.68% |
| Mar 31, 2021 | -875.26% |
| Dec 31, 2020 | -576.86% |
| Sep 30, 2020 | 14.30% |
| Jun 30, 2020 | -291.55% |
| Mar 31, 2020 | -814.54% |
| Dec 31, 2019 | -320.92% |
| Sep 30, 2019 | -898.86% |
| Jun 30, 2019 | -1,530.00% |
| Mar 31, 2019 | -1,510.97% |
| Dec 31, 2018 | -429.04% |
| Sep 30, 2018 | -111.98% |
| Jun 30, 2018 | -537.94% |
| Mar 31, 2018 | -803.64% |
| Sep 30, 2017 | -425.80% |
| Jun 30, 2017 | -843.24% |
| Mar 31, 2017 | -4,490.76% |
| Dec 31, 2016 | -4,341.20% |
| Sep 30, 2016 | -2,200.10% |
| Jun 30, 2016 | -566.71% |
| Mar 31, 2016 | -2,216.02% |
| Dec 31, 2015 | -1,562.25% |
| Sep 30, 2015 | -1,101.79% |
| Jun 30, 2015 | -6,225.15% |